Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-type (Cav2.2) and T-type (Cav3.1, Cav3.2, Cav3.3) voltage-gated calcium channels are essential proteins that regulate the entry of calcium ions into cells in response to membrane depolarization. N-type channels are primarily located at presynaptic nerve terminals, where they facilitate the release of neurotransmitters such as glutamate and substance P, playing a vital role in pain transmission and sympathetic nervous system signaling (Catterall, 2011). T-type channels are low-voltage-activated channels found in various tissues, including the heart's sinoatrial node and the thalamus, where they contribute to pacemaker activity and rhythmic neuronal firing (Perez-Reyes, 2003). While conventional calcium channel blockers (CCBs) target L-type channels, newer agents like cilnidipine and benidipine also inhibit N-type and T-type channels to provide broader clinical benefits (Takahara, 2009). Blockade of N-type channels can reduce sympathetic overactivity and provide analgesic effects, while T-type blockade is associated with improved renal hemodynamics and anti-arrhythmic properties (Yao et al., 2006). These channels are therefore significant therapeutic targets for managing hypertension, chronic pain, and epilepsy, offering a more nuanced approach to cardiovascular and neurological care than L-type specific blockers.
Inhibition of calcium ion influx through the pore-forming alpha-1 subunits of N-type (Cav2.2) and T-type (Cav3.1, Cav3.2, Cav3.3) voltage-gated calcium channels, leading to reduced neurotransmitter release and decreased cellular excitability (Catterall, 2011; Perez-Reyes, 2003).
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-type and T-type voltage-gated calcium channels (Cav2.2 and Cav3.x).